Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM antibodies are having a direct co-stimulatory effect on immune cells in addition to interfering with the CEACAM1 check-point blockade on immune cells. The proprietary antibodies are based on the research of Prof. Bernhard B. Singer, University of Duisburg/Essen in Germany, which has been described in several Nature publications.